Technology partnership hopes to improve outcomes for type 2 diabetics

Diabetes care company Ascensia Diabetes Care and therapeutic companion software provider Voluntis have announced a partnership to help improve the lives of type 2 diabetics.

The partnership intends to optimise insulin management by connecting Volunits’ basal insulin management solution with blood glucose monitoring systems from Ascensia.

Ascensia’s Contour Next One and Contour Plus One blood glucose monitoring systems will connect via Bluetooth to Voluntis’ digital solution, Insulia. Ascensia’s systems will provide blood glucose readings to calculate basal insulin dosing for people with type 2 diabetes. The companies hope that by linking blood glucose data to digital management software, patients will be able to self-manage their insulin doses.

Ascensia’s blood glucose monitoring systems feature smart meters that link to mobile devices. The systems connect with an app that collects and analyses blood glucose measurements provided by the device.

Voluntis’ Insulia is a prescription-only medical device that provides type 2 diabetics with insulin dose recommendations and educational coaching messages through a smartphone app based on blood glucose values and other data.

Michael Kloss, CEO of Ascensia Diabetes Care, said: “Type 2 diabetes is a complex condition, especially for people using insulin therapy as part of their management. We’re excited to be working together with Voluntis to empower people with Type 2 diabetes by helping them to better manage their insulin treatment. This partnership helps us move further towards our ambition of providing integrated diabetes management, which we see as the future. It is our first partnership in the area of medication management, which is a critical component of integrated diabetes management, and we see Voluntis as a key partner in helping to deliver this goal.”

Pierre Leurent, CEO of Voluntis added: “We are delighted to start this collaboration with Ascensia in order to provide a seamless combination of Bluetooth-enabled blood glucose monitoring systems with digital insulin therapy optimisation. Joining forces will help us simplify how people manage their blood sugars from end-to-end so they can vastly improve their quality of life.”